康柏西普治疗继发黄斑水肿临床研究

Clinical study of Conbercept in treatment of secondary macular edema

目的探讨玻璃体腔内注射康柏西普治疗视网膜血管性疾病继发黄斑水肿(ME)疗效及安全性。方法对30例(30眼)玻璃体腔内注射康柏西普治疗视网膜血管性疾病继发黄斑水肿患者展开回顾性分析。通过常规眼科检查:视力、彩色眼底照相、光学相干断层扫描(OCT)等,筛选出黄斑水肿患者,采用玻璃体注射1个月1次,连续3次,必要时重复注射的方法,通过OCT)黄斑中心凹的厚度进行精准测量,并根据其具体结果决定是否再次注射。观察治疗前、后1、3、6个月最佳矫正视力、黄斑中心凹的变化。结果玻璃体腔内注射康柏西普1、3、6个月平均最佳矫正视力皆有所提高,差异具有统计学意义(P<0.05)。结论玻璃体腔内注射康柏西普治疗视网膜血管性疾病继发黄斑水肿能够有效改善视力,疗效安全可靠。

Objective To investigate the clinical efficacy and safety of intravitreal injection of Conbercept in the treatment of macular edema（ME）secondary to retinal vascular disease.Methods A retrospective analysis was performed on 30 cases（30 eyes）of intravitreal injection of Conpacept in the treatment of macular edema secondary to retinal vascular disease.Patients with macular edema were selected through routine ophthalmological examinations including visual acuity,color fundus photography,optical coherence tomography（OCT）,etc.Using the 3＋ prn method,the thickness of the macular fovea was accurately measured by optical coherence tomography（OCT）.We decided whether to reinject according to these results.The best corrected acuity and the changes of macular fovea were observed before and after 1,3 and 6 months of treatment.Results The mean best corrected acuity（BCVA）was improved to some extent at 1,3 and 6 months after treatment.The difference was statistically significant（P〈0.05）.Conclusion Intravitreal injection of Conbercept for treatment of macular edema secondary to retinal vascular disease can effectively improve acuity,efficacy is safe and reliable.